CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 150 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01924754
NCT01924754N/ACompleted
CompareCT.gov

GINI: Gardasil Immunogenicity With Needle-free Injection-Safety and Immunogenicity of Gardasil Using IM and ID Needle-free Injection Delivery

University of California, San Francisco·observational·Posted Aug 16, 2013·Updated Oct 13, 2021

In Brief

An observational study for HPV Seroconversion. Completed, enrolled 150 participants across 2 sites in 2 countries.

Detailed Summary

Using biospecimens collected in a trial by the Thai Red Cross AIDS Research Center that studied two new human papillomavirus (HPV) vaccine delivery regimens, the investigators at UCSF will be testing the serum for antibodies to measure the strength of their response to the vaccine.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHPV Seroconversion
CountriesThailand, United States
CollaboratorsMerck Sharp & Dohme LLC

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedAug 16, 2013
Enrollment StartJan 1, 2014
Primary CompletionMay 31, 2016
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 12.9 years ago